Helix BioPharma Corp., a biopharmaceutical company, develops drugs for the prevention and treatment of cancer based on its proprietary technologies. The company distributes Klean-Prep that is used for bowel lavage/evacuation, primarily as a pre-treatment for colon examination in colorectal cancer screening; Orthovisc and Monovisc, which reduce joint inflammation and improves joint mobility providing relief from osteoarthritis of the knee; Imunovir, an immune system modulating drug; and Normacol, a bulk forming laxative. It also focuses on the development of L-DOS47 that is in Phase I/II clinical trial stage for the treatment of inoperable, locally advanced, and recurrent or metastatic non-small cell lung cancer; and Topical Interferon Alpha-2b, which has completed phase II study for the treatment of low-grade cervical lesions and ano-genital warts caused by human papilloma virus infections. The company markets products to physicians and pharmacists through a combination of sales representatives and targeted direct mail programs in Canada. Helix BioPharma Corp. is headquartered in Aurora, Canada.

Key Statistics